AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$MGNX

MGNX 8-K & SEC Filings - Yahoo Finance

MacroGenics (MGNX) filed an 8-K with the SEC on October 23, 2026, reporting corporate changes and voting matters. The filing includes exhibits related to the disclosure. Investors should review the details for potential impacts on the company's governance and operations.

Original reporting
finance.yahoo.com
Published Oct 24, 2026, 9:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 6:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$MGNX
Neutral
low confidence
Mentioned
$MGNX
Relevance
4/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$MGNXNeutralLow
01

Why it matters

The filing itself does not contain substantive data; its primary value is signaling that a material event may be forthcoming.

02

Market read

Low immediate relevance; investors should monitor for follow‑up disclosures.

03

What to watch

Potential upcoming shareholder vote or restructuring not yet detailed.

Relevance 4/10Novelty 3/10Timing: today

Background

MGNX filed an 8‑K covering corporate changes and voting matters, typical for companies reporting material events to the SEC.

Company-level read

Ticker impact

$MGNXNeutralLow confidence
Context

The article reports the filing of an 8‑K for MGNX, indicating corporate changes and voting matters.

Expected impact

minimal pressure as investors await further details

Evidence & confidence

Without disclosed terms or numbers, traders have little actionable information.

Market effects

Sector

None disclosed

Regional

None disclosed

Global

None disclosed

Counterpoint

What could challenge this read

If the filing hints at a pending strategic move, early positioning could be considered.

Key entities

  • Company
    MGNX

    Issuer of the 8‑K filing.

Read at source← All news

Related articles

$MGNXMed

MacroGenics Updates Clinical Pipeline, Reports $288M in Cash and Runway Through 2028

MacroGenics reported $288M in cash as of September 30, 2026, and a runway through 2028. Clinical updates include MGC026's 27.3% response rate in SCCHN, lorigerlimab's 25% response in clear cell gynecologic cancer, and MGC028's Phase 1 completion. The company expects further updates in mid-2027 and the first half of 2027, respectively. MacroGenics also noted $359M in non-dilutive capital generated in 2025-2026.

tradingview.com
$MGNXMed

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress • Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels • Reported interim results at ESMO in both Phase 1 stud

SEC EDGAR 8-K
$MGNXMedAI 8/10

MacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results;

MacroGenics (MGNX) reported interim Phase 2 results for lorigerlimab, showing 25% objective response rate in advanced clear cell gynecologic cancer (CCGC) patients. The study included 41 patients, with 16 evaluable for response. MGNX is expanding the trial, aiming to enroll 20 more CCGC patients. The stock traded at $2.25 on October 23, 2026, and is down 7.69% in pre-market trading.

rttnews.com
$MGNXMedAI 9/10

MacroGenics' Lorigerlimab Shows 25% Response Rate In Clear Cell Gynecologic Cancer

MacroGenics (MGNX) reported Phase 2 trial results for lorigerlimab, showing a 25% response rate and 44% disease control rate in advanced clear cell gynecologic cancer. All responses were ongoing as of September 1, 2026. The company is testing a lower dose, with updated results expected in H1 2027. MGNX shares closed at $2.25 on Friday, down 38.02%, and were down 1.33% in pre-market trading.

rttnews.com